Abstract
Alzheimer’s disease (AD) is a neurodegenerative disease characterized by a progressive loss in memory and cognitive abilities. One of the key pathologic features of AD is the accumulation of beta amyloid (Aβ). Somatostatin has been shown to regulate neuronal neprilysin activity, a key enzyme involved in Aβ catabolism. The actions of somatostatin are mediated through somatostatin receptors 1-5. The somatostatin subtype-4 receptor (sst4) is expressed in key regions of the brain impacted by AD. Thus, sst4 agonists may serve as disease modifying agents (i.e., preventative), enhancing enzymatic activity and decreasing neurotoxic Aβ species within key brain regions of AD patients. This chapter will address the viability of such sst4 agonists within the context of AD therapy, in conjunction with strategies for design, synthesis, and recognition at the macromolecular level.
Keywords: Alzheimer’s disease, amyloid cascade hypothesis, beta amyloid, G protein coupled receptors, homology modeling, model building, somatostatin receptor subtype 4, somatostatin receptors, neprilysin, tau hypothesis, virtual screening.
Related Journals
Current Drug Delivery
Current Bioactive Compounds
Current Drug Safety
Reviews on Recent Clinical Trials
Drug Delivery Letters
Recent Advances in Drug Delivery and Formulation
Recent Advances in Anti-Infective Drug Discovery
Drug Metabolism and Bioanalysis Letters
Applied Drug Research, Clinical Trials and Regulatory Affairs
Current Drug Targets - Inflammation & Allergy
Related Books
A Comprehensive Text Book on Self-emulsifying Drug Delivery Systems
Angiogenesis & Therapeutic Targets In Cancer
Anti-Angiogenesis Drug Discovery and Development
Anti-Angiogenesis Drug Discovery and Development
Anti-Angiogenesis Drug Discovery and Development
Anti-Angiogenesis Drug Discovery and Development
Anti-Angiogenesis Drug Discovery and Development
Biopolymers In Drug Delivery: Recent Advances and Challenges
Chemoinformatics: Directions Toward Combating Neglected Diseases
Current Advances in Drug Delivery Through Fast Dissolving/Disintegrating Dosage Forms